**B.1 510(k) Summary of Safety & Effectiveness**

(as required by 21 CFR § 807.92c)

Date Prepared: August 15, 2008

Submitted by:

Hologic, Inc.
35 Crosby Drive
Bedford, MA 01730, USA

Name, Title and Phone Number of Contact:

Catherine A. Williams
Director, Regulatory Affairs
Phone: (408) 745-5128
FAX: (408) 744-1905
Email: catherine.williams@hologic.com

Trade Name and Common Name:

<table>
<thead>
<tr>
<th>Trade Name:</th>
<th>Quantra™</th>
</tr>
</thead>
<tbody>
<tr>
<td>Software Version:</td>
<td>1.1</td>
</tr>
<tr>
<td>Common Name:</td>
<td>Picture Archiving and Communications System</td>
</tr>
</tbody>
</table>

Classification:

| Regulatory Class: | II |
| Classification Panel: | Radiology |

Image Processing System 21 CFR § 892.2050 Product Code 90-LLZ

Predicate Devices:

The predicate devices for Quantra software are certain software functions contained in the following devices:

K050196, Feb 24, 2005  Sectra IDS5 Workstation [Sectra Imtec AB]
K073272, Dec 11, 2007  WorkstationOne™ Breast Imaging Workstation [Three Palm Software, LLC]

Device Description:

Quantra is a software application that estimates breast tissue volumes. The estimations are made from mammography images produced by full-field digital mammography (FFDM) systems.
Hologic, Inc.

Quantra has been designed and will be manufactured in accordance with the following standards:

- ISO 13485 Medical Devices – Quality Management Systems
- ISO 14971 Medical Devices – Application of Risk Management to Medical Devices
- NEMA DICOM PS 3 Digital Imaging and Communications in Medicine (DICOM) Set. (Radiology) (ISO 12052)
- 21 CFR § 820 US Food and Drug Administration, Quality System Regulation
- N/A General Principles of Software Validation; Final Guidance for Industry and FDA

The performance of the software is also tested in accordance with Hologic’s SOPs and testing procedures to demonstrate adequate performance.

Intended Use:

Quantra™ is a software application intended for use with Hologic digital mammography systems. Quantra calculates volumetric breast density as a ratio of fibroglandular tissue and total breast volume estimates. Quantra provides these numerical values for each breast to aid radiologists in the assessment of breast tissue composition. Quantra produces adjunctive information; it is not an interpretive or diagnostic aid.

Quantra is a software application which runs on the Hologic Cenova DICOM server (Class I exempt per 21 CFR § 892.2010 and 21 CFR § 892.2020).

Technological Characteristics:

Quantra is a software application that processes digital mammography images. The device does not contact the patient, nor does it control any life-sustaining devices.

General Safety and Effectiveness Concerns:

The device labeling contains instructions for use and any necessary cautions and warnings to provide for safe and effective use of this device. Risk management is ensured via a risk analysis, which is used to identify potential hazards. These potential hazards are controlled via software development, verification and validation testing.

Conclusion:

The 510(k) Pre-Market Notification for Quantra contains adequate information and data to enable FDA-CDRH to determine substantial equivalence to the predicate devices. The submission contains the results of a hazard analysis and the "Level of Concern" for potential hazards has been classified as "Minor".
Hologic, Inc.
% Mr. Mark Job
Responsible Third Party Official
Regulatory Technology Services LLC
1394 25th Street NW
BUFFALO MN 55313

Re: K082483
   Trade/Device Name: Quantra™
   Regulation Number: 21 CFR 892.2050
   Regulation Name: Picture archiving and communications system
   Regulatory Class: II
   Product Code: LLZ
   Dated: August 27, 2008
   Received: August 28, 2008

Dear Mr. Job:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:

- 21 CFR 876.xxx (Gastroenterology/Renal/Urology) 240-276-0115
- 21 CFR 884.xxx (Obstetrics/Gynecology) 240-276-0115
- 21 CFR 894.xxx (Radiology) 240-276-0120
- Other 240-276-0100

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometrics' (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Joyce M. Whang, Ph.D.
Acting Director, Division of Reproductive, Abdominal, and Radiological Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure
B.2 Indication(s) for Use Statement

510(k) Number (if known):  K082483

Device Name: Quantra™

Indications for Use:

Quantra™ is a software application intended for use with Hologic digital mammography systems. Quantra calculates volumetric breast density as a ratio of fibroglandular tissue and total breast volume estimates. Quantra provides these numerical values for each breast to aid radiologists in the assessment of breast tissue composition. Quantra produces adjunctive information; it is not an interpretive or diagnostic aid.

Quantra is a software application which runs on the Hologic Cenova DICOM server (Class I exempt per 21 CFR § 892.2010 and 21 CFR § 892.2020).

(Please do not write below this line—continue on another page if needed)

Concurrence of CDRH, Office of Device Evaluation (ODE)